Polycystic Ovarian Syndrome Treatment Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global polycystic ovarian syndrome treatment market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the polycystic ovarian syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Polycystic Ovarian Syndrome Treatment market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider polycystic ovarian syndrome treatment market, and compares it with other markets.
Scope
Markets Covered: 1) By Drug Type: Oral Contraceptives; Ornithine Decarboxylase Inhibitors; Insulin-Sensitizing Agents; Anti-Depressants; Diuretics; Aromatase Inhibitors; 2) By Surgery Type: Ovarian Wedge Resection; Laparoscopic Ovarian Drilling
Companies Mentioned: Bristol-Myer Squibb Company; Bayer AG; Pfizer, Inc.; Merck KGaA; Sanofi
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the polycystic ovarian syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Polycystic Ovarian Syndrome Treatment market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider polycystic ovarian syndrome treatment market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
- The polycystic ovarian syndrome treatment market section of the report gives context. It compares the polycystic ovarian syndrome treatment market with other segments of the polycystic ovarian syndrome treatment market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, polycystic ovarian syndrome treatment indicators comparison.
Scope
Markets Covered: 1) By Drug Type: Oral Contraceptives; Ornithine Decarboxylase Inhibitors; Insulin-Sensitizing Agents; Anti-Depressants; Diuretics; Aromatase Inhibitors; 2) By Surgery Type: Ovarian Wedge Resection; Laparoscopic Ovarian Drilling
Companies Mentioned: Bristol-Myer Squibb Company; Bayer AG; Pfizer, Inc.; Merck KGaA; Sanofi
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Executive Summary2. Polycystic Ovarian Syndrome Treatment Market Characteristics26. Key Mergers And Acquisitions In The Polycystic Ovarian Syndrome Treatment Market27. Polycystic Ovarian Syndrome Treatment Market Trends And Strategies28. Polycystic Ovarian Syndrome Treatment Market Future Outlook and Potential Analysis
3. Polycystic Ovarian Syndrome Treatment Market Size And Growth
4. Polycystic Ovarian Syndrome Treatment Market Segmentation
5. Polycystic Ovarian Syndrome Treatment Market Regional And Country Analysis
6. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market
7. China Polycystic Ovarian Syndrome Treatment Market
8. India Polycystic Ovarian Syndrome Treatment Market
9. Japan Polycystic Ovarian Syndrome Treatment Market
10. Australia Polycystic Ovarian Syndrome Treatment Market
11. Indonesia Polycystic Ovarian Syndrome Treatment Market
12. South Korea Polycystic Ovarian Syndrome Treatment Market
13. Western Europe Polycystic Ovarian Syndrome Treatment Market
14. UK Polycystic Ovarian Syndrome Treatment Market
15. Germany Polycystic Ovarian Syndrome Treatment Market
16. France Polycystic Ovarian Syndrome Treatment Market
17. Eastern Europe Polycystic Ovarian Syndrome Treatment Market
18. Russia Polycystic Ovarian Syndrome Treatment Market
19. North America Polycystic Ovarian Syndrome Treatment Market
20. USA Polycystic Ovarian Syndrome Treatment Market
21. South America Polycystic Ovarian Syndrome Treatment Market
22. Brazil Polycystic Ovarian Syndrome Treatment Market
23. Middle East Polycystic Ovarian Syndrome Treatment Market
24. Africa Polycystic Ovarian Syndrome Treatment Market
25. Polycystic Ovarian Syndrome Treatment Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
The polycystic ovarian syndrome treatment market consists of sale of services and related products that are used in hospital pharmacies, drug stores, and retail pharmacies to treat polycystic ovarian syndrome. The polycystic ovarian syndrome is a disorder in which hormones are out of control for females and have male hormones that are higher than normal, which causes them to skip menstrual periods and makes pregnancy more difficult for them.The global polycystic ovarian syndrome treatment market was worth $3.83 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 5.00% and reach $4.65 billion by 2023.
The polycystic ovarian syndrome treatment market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America was the largest region .
The polycystic ovarian syndrome treatment market covered in this report is segmented by drug type into oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, aromatase inhibitors. It is also segmented by surgery type into ovarian wedge resection and laparoscopic ovarian drilling.
The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS is a prevalent hormonal disorder among premenopausal women worldwide, with reproductive, endocrine, and metabolic abnormalities. The PCOS prevalence ranges from 2.2% to 26% globally and is highly variable. In China, the figures range between 2% to 7.5%, and 6.3% in Sri Lanka, 9.13% in in south India and 22.5% in Maharashtra. The rise in genetic and hormonal disorders globally is expected to increase the growth of the polycystic ovarian syndrome treatment market.
Lack of drugs approved by regulatory bodies such as FDA (Food and Drug Administration) among many countries is a key factor hampering the growth of the polycystic ovarian syndrome treatment market. FDA has not approved pharmacological treatment for use in adolescents with PCOS. However, some pharmacological interventions are used to treat PCOS symptoms. In 2017, FDA removed sibutramine (a sympathomimetic core appetite suppressant) from the US market due to concerns about increased Cardiovascular disease (CVD) events with its use. Additionally, rimonabant, a key appetite suppressant cannabinoid CB1 receptor antagonist was not approved in the USA due to concerns about suicidal ideation and drug overdoses. Therefore, the lack of regulatory body approved drugs in many countries is a key factor restraining the growth of the polycystic ovarian syndrome treatment market.
Laparoscopic ovarian drilling is a major trend driving the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a surgical treatment performed by the doctors in critical conditions that can cause ovulation in women with polycystic ovary syndrome (PCOS). Ovarian drilling is often used by women with PCOS who often do not ovulate despite having attempted weight loss and use of fertility drugs. According to the study published in 2019 by the Department of Gynecology and Obstetrics in major hospitals in France, after laparoscopic drilling, 47.4% (137 patients) had pregnancy and 51.8% (71 patients) of these were spontaneous. 16.6% (48 patients) women had at least two pregnancies after drilling and 56.3% (27 patients) of these were spontaneous. 33 women received second drillings. Of these, 57.6% (19 patients) achieved at least one pregnancy, within this 52.6% (10 patients) were spontaneous.
In July 2019, Eurolife Healthcare Pvt. Ltd, a Mumbai based company, manufactures and distributes an exclusive portfolio of healthcare formulations, Intravenous Infusions, Ophthalmic, Sterilized water for Injections, Nebules, Tablets, Capsules, Ointment & Creams, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition helped the company to tap and service its European and the US markets for intravenous infusions in a better way. Teva Pharmaceutical Industries Ltd., a multinational pharmaceutical company, develops, manufactures, and markets generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients.
Major players in the market are Bristol-Myer Squibb Company, Bayer AG, Pfizer, Inc., Merck KGaA, Sanofi, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott and Addex Therapeutics Ltd.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myer Squibb Company
- Bayer AG
- Pfizer, Inc.
- Merck KGaA
- Sanofi
- AstraZeneca
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Abbott
- Addex Therapeutics Ltd
- BIOCAD
- Allergan plc.
- Johnson and Johnson
- Ferring BV
- Ferring Pharmaceuticals, Inc.
Methodology
LOADING...
